+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neuropathic Pain Drug Market Research Report by Type, by Diagnosis, by Indication, by End User, by Distribution, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4968619
  • Report
  • July 2021
  • Region: Global
  • 185 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Neuropathic Pain Drug Market will Grow to USD 15,236.50 Million by 2026, at a CAGR of 9.57%

FEATURED COMPANIES

  • Abbott
  • AstraZeneca
  • Collegium Pharmaceuticals
  • Eli Lily and Company
  • Grünenthal
  • Novartis International AG
  • MORE
The Global Neuropathic Pain Drug Market size was estimated at USD 8,800.80 Million in 2020 and expected to reach USD 9,614.04 Million in 2021, at a Compound Annual Growth Rate (CAGR) 9.57% to reach USD 15,236.50 Million by 2026.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Neuropathic Pain Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type, the Neuropathic Pain Drug Market was studied across Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy, and Trigeminal Neuralgia.
  • Based on Treatment, the Neuropathic Pain Drug Market was studied across Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type is further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type is further studied across Ibuprofen and Naproxen.
  • Based on Diagnosis, the Neuropathic Pain Drug Market was studied across Blood Tests and Imaging Physical Examination. The Imaging Physical Examination is further studied across CT, Electromyography, and MRI.
  • Based on Indication, the Neuropathic Pain Drug Market was studied across Diabetic Neuropathy and Spinal Stenosis.
  • Based on End User, the Neuropathic Pain Drug Market was studied across Clinics and Hospitals.
  • Based on Distribution, the Neuropathic Pain Drug Market was studied across Online Pharmacies and Retail Pharmacies & Drug Stores.
  • Based on Region, the Neuropathic Pain Drug Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neuropathic Pain Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Neuropathic Pain Drug Market, including Abbott, Allergan, Inc., Astellas, AstraZeneca, Bausch Health Companies Inc., Baxter Healthcare Corporation, Biogen Idec Inc., Bristol-Myers Squibb and Company, Cara Therapeutics, CODA Biotherapeutics, Inc., Collegium Pharmaceuticals, Depomed, Depomed Inc., Eli Lily and Company, Endo International plc, GlaxoSmithKline PLC, Grünenthal, GSK, Johnson & Johnson Services Inc., Mallinckrodt Pharmaceuticals, Neuroheal Biomedicals, Novartis International AG, Pacira BioSciences, Pfizer Inc., Purdue Pharma L.P., Sanofi S.A., and Teva Pharmaceutical Industries Ltd.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Neuropathic Pain Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neuropathic Pain Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neuropathic Pain Drug Market?
4. What is the competitive strategic window for opportunities in the Global Neuropathic Pain Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Neuropathic Pain Drug Market?
6. What is the market share of the leading vendors in the Global Neuropathic Pain Drug Market?
7. What modes and strategic moves are considered suitable for entering the Global Neuropathic Pain Drug Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • AstraZeneca
  • Collegium Pharmaceuticals
  • Eli Lily and Company
  • Grünenthal
  • Novartis International AG
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Type Outlook
3.4. Treatment Outlook
3.5. Diagnosis Outlook
3.6. Indication Outlook
3.7. End User Outlook
3.8. Distribution Outlook
3.9. Region Outlook
3.10. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of chronic diseases such as diabetes and cancer globally
5.1.1.2. Rising advancement of healthcare systems across the world
5.1.1.3. Availability of numerous approved drugs at retail pharmacies
5.1.2. Restraints
5.1.2.1. Probable side effects that could lead to death
5.1.3. Opportunities
5.1.3.1. Surge in awareness related to neuropathic pain in emerging economies
5.1.3.2. Ongoing technological innovations and development of drugs
5.1.4. Challenges
5.1.4.1. Concerns over incomplete pain relief
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Neuropathic Pain Drug Market, by Type
6.1. Introduction
6.2. Phantom Limb Pain
6.3. Post Herpetic Neuralgia
6.4. Post-traumatic Neuropathy
6.5. Trigeminal Neuralgia

7. Neuropathic Pain Drug Market, by Treatment
7.1. Introduction
7.2. Antidepressant Drugs Type
7.2.1. Serotonin Noradrenaline
7.2.2. Tricyclic Antidepressants
7.3. Medication Type
7.4. Multimodal Therapy
7.5. NSAIDs Type
7.5.1. Ibuprofen
7.5.2. Naproxen

8. Neuropathic Pain Drug Market, by Diagnosis
8.1. Introduction
8.2. Blood Tests
8.3. Imaging Physical Examination
8.3.1. CT
8.3.2. Electromyography
8.3.3. MRI

9. Neuropathic Pain Drug Market, by Indication
9.1. Introduction
9.2. Diabetic Neuropathy
9.3. Spinal Stenosis

10. Neuropathic Pain Drug Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals

11. Neuropathic Pain Drug Market, by Distribution
11.1. Introduction
11.2. Online Pharmacies
11.3. Retail Pharmacies & Drug Stores

12. Americas Neuropathic Pain Drug Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Neuropathic Pain Drug Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Thailand

14. Europe, Middle East & Africa Neuropathic Pain Drug Market
14.1. Introduction
14.2. France
14.3. Germany
14.4. Italy
14.5. Netherlands
14.6. Qatar
14.7. Russia
14.8. Saudi Arabia
14.9. South Africa
14.10. Spain
14.11. United Arab Emirates
14.12. United Kingdom

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion

16. Company Usability Profiles
16.1. Abbott
16.2. Allergan, Inc.
16.3. Astellas
16.4. AstraZeneca
16.5. Bausch Health Companies Inc.
16.6. Baxter Healthcare Corporation
16.7. Biogen Idec Inc.
16.8. Bristol-Myers Squibb and Company
16.9. Cara Therapeutics
16.10. CODA Biotherapeutics, Inc.
16.11. Collegium Pharmaceuticals
16.12. Depomed
16.13. Depomed Inc.
16.14. Eli Lily and Company
16.15. Endo International plc
16.16. GlaxoSmithKline PLC
16.17. Grünenthal
16.18. GSK
16.19. Johnson & Johnson Services Inc.
16.20. Mallinckrodt Pharmaceuticals
16.21. Neuroheal Biomedicals
16.22. Novartis International AG
16.23. Pacira BioSciences
16.24. Pfizer Inc.
16.25. Purdue Pharma L.P.
16.26. Sanofi S.A.
16.27. Teva Pharmaceutical Industries Ltd

17. Appendix
17.1. Discussion Guide
17.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2020 (USD MILLION)
FIGURE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2020 (USD MILLION)
FIGURE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2020 (USD MILLION)
FIGURE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2020 (USD MILLION)
FIGURE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2020 (USD MILLION)
FIGURE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2020 (USD MILLION)
FIGURE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2020 (USD MILLION)
FIGURE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET: MARKET DYNAMICS
FIGURE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
FIGURE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2020 VS 2026 (USD MILLION)
FIGURE 14. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2026
FIGURE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PHANTOM LIMB PAIN, 2018-2026 (USD MILLION)
FIGURE 16. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PHANTOM LIMB PAIN, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 17. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST HERPETIC NEURALGIA, 2018-2026 (USD MILLION)
FIGURE 18. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST HERPETIC NEURALGIA, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 19. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-TRAUMATIC NEUROPATHY, 2018-2026 (USD MILLION)
FIGURE 20. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-TRAUMATIC NEUROPATHY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 21. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRIGEMINAL NEURALGIA, 2018-2026 (USD MILLION)
FIGURE 22. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 23. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2020 VS 2026 (%)
FIGURE 24. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2020 VS 2026 (USD MILLION)
FIGURE 25. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2026
FIGURE 26. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2026 (USD MILLION)
FIGURE 27. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 28. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SEROTONIN NORADRENALINE, 2018-2026 (USD MILLION)
FIGURE 29. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SEROTONIN NORADRENALINE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 30. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2026 (USD MILLION)
FIGURE 31. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 32. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY MEDICATION TYPE, 2018-2026 (USD MILLION)
FIGURE 33. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY MEDICATION TYPE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 34. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY MULTIMODAL THERAPY, 2018-2026 (USD MILLION)
FIGURE 35. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY MULTIMODAL THERAPY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 36. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2026 (USD MILLION)
FIGURE 37. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 38. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY IBUPROFEN, 2018-2026 (USD MILLION)
FIGURE 39. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY IBUPROFEN, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 40. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NAPROXEN, 2018-2026 (USD MILLION)
FIGURE 41. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NAPROXEN, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 42. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2020 VS 2026 (%)
FIGURE 43. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2020 VS 2026 (USD MILLION)
FIGURE 44. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2026
FIGURE 45. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY BLOOD TESTS, 2018-2026 (USD MILLION)
FIGURE 46. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY BLOOD TESTS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 47. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2018-2026 (USD MILLION)
FIGURE 48. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 49. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CT, 2018-2026 (USD MILLION)
FIGURE 50. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CT, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 51. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ELECTROMYOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 52. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ELECTROMYOGRAPHY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 53. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY MRI, 2018-2026 (USD MILLION)
FIGURE 54. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY MRI, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 55. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2020 VS 2026 (%)
FIGURE 56. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2020 VS 2026 (USD MILLION)
FIGURE 57. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2026
FIGURE 58. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, 2018-2026 (USD MILLION)
FIGURE 59. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 60. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPINAL STENOSIS, 2018-2026 (USD MILLION)
FIGURE 61. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPINAL STENOSIS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 62. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2020 VS 2026 (%)
FIGURE 63. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2020 VS 2026 (USD MILLION)
FIGURE 64. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2026
FIGURE 65. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CLINICS, 2018-2026 (USD MILLION)
FIGURE 66. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CLINICS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 67. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS, 2018-2026 (USD MILLION)
FIGURE 68. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 69. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (%)
FIGURE 70. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (USD MILLION)
FIGURE 71. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2026
FIGURE 72. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ONLINE PHARMACIES, 2018-2026 (USD MILLION)
FIGURE 73. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 74. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, 2018-2026 (USD MILLION)
FIGURE 75. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 76. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 77. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 78. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 79. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 80. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 81. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 82. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 83. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 84. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 85. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 86. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 87. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 88. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 89. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 90. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 91. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 92. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 93. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 94. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 95. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 96. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 97. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 98. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 99. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 100. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 101. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 102. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 103. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 104. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 105. GLOBAL NEUROPATHIC PAIN DRUG MARKET: FPNV POSITIONING MATRIX
FIGURE 106. GLOBAL NEUROPATHIC PAIN DRUG MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 107. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL NEUROPATHIC PAIN DRUG MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL NEUROPATHIC PAIN DRUG MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PHANTOM LIMB PAIN, BY REGION, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST HERPETIC NEURALGIA, BY REGION, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-TRAUMATIC NEUROPATHY, BY REGION, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, BY REGION, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SEROTONIN NORADRENALINE, BY REGION, 2018-2026 (USD MILLION)
TABLE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2026 (USD MILLION)
TABLE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY MEDICATION TYPE, BY REGION, 2018-2026 (USD MILLION)
TABLE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY MULTIMODAL THERAPY, BY REGION, 2018-2026 (USD MILLION)
TABLE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, BY REGION, 2018-2026 (USD MILLION)
TABLE 16. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2026 (USD MILLION)
TABLE 17. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2026 (USD MILLION)
TABLE 18. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD MILLION)
TABLE 19. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2026 (USD MILLION)
TABLE 20. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, BY REGION, 2018-2026 (USD MILLION)
TABLE 21. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CT, BY REGION, 2018-2026 (USD MILLION)
TABLE 22. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ELECTROMYOGRAPHY, BY REGION, 2018-2026 (USD MILLION)
TABLE 23. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY MRI, BY REGION, 2018-2026 (USD MILLION)
TABLE 24. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2026 (USD MILLION)
TABLE 25. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2026 (USD MILLION)
TABLE 26. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPINAL STENOSIS, BY REGION, 2018-2026 (USD MILLION)
TABLE 27. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2026 (USD MILLION)
TABLE 28. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2026 (USD MILLION)
TABLE 29. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2026 (USD MILLION)
TABLE 30. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD MILLION)
TABLE 31. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2026 (USD MILLION)
TABLE 32. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2026 (USD MILLION)
TABLE 33. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 34. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 35. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 36. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 37. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 38. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 39. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 40. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 41. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 42. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 43. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 44. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 45. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 46. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 47. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 48. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 49. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 51. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 52. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 53. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 54. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 55. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 56. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 57. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 58. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 59. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 60. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 61. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 62. GLOBAL NEUROPATHIC PAIN DRUG MARKET: SCORES
TABLE 63. GLOBAL NEUROPATHIC PAIN DRUG MARKET: BUSINESS STRATEGY
TABLE 64. GLOBAL NEUROPATHIC PAIN DRUG MARKET: PRODUCT SATISFACTION
TABLE 65. GLOBAL NEUROPATHIC PAIN DRUG MARKET: RANKING
TABLE 66. GLOBAL NEUROPATHIC PAIN DRUG MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 67. GLOBAL NEUROPATHIC PAIN DRUG MARKET: MERGER & ACQUISITION
TABLE 68. GLOBAL NEUROPATHIC PAIN DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 69. GLOBAL NEUROPATHIC PAIN DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 70. GLOBAL NEUROPATHIC PAIN DRUG MARKET: INVESTMENT & FUNDING
TABLE 71. GLOBAL NEUROPATHIC PAIN DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 72. GLOBAL NEUROPATHIC PAIN DRUG MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Abbott
  • Allergan, Inc.
  • Astellas
  • AstraZeneca
  • Bausch Health Companies Inc.
  • Baxter Healthcare Corporation
  • Biogen Idec Inc.
  • Bristol-Myers Squibb and Company
  • Cara Therapeutics
  • CODA Biotherapeutics, Inc.
  • Collegium Pharmaceuticals
  • Depomed
  • Depomed Inc.
  • Eli Lily and Company
  • Endo International plc
  • GlaxoSmithKline PLC
  • Grünenthal
  • GSK
  • Johnson & Johnson Services Inc.
  • Mallinckrodt Pharmaceuticals
  • Neuroheal Biomedicals
  • Novartis International AG
  • Pacira BioSciences
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll